Dysplastic nevi as a melanoma risk factor in patients with familial melanoma
β Scribed by William P. Carey Jr.; C. Jean Thompson; Marie Synnestvedt; Dupont Guerry IV; Allan Halpern; Delray Schultz; David E. Elder
- Publisher
- John Wiley and Sons
- Year
- 1994
- Tongue
- English
- Weight
- 775 KB
- Volume
- 74
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Background:
Familial melanoma has been associated with "clinically atypical moles" or "dysplastic nevi," (dn) which are markers for increased melanoma risk. in addition, melanomas in these kindreds present at a younger age, and tend to be multiple.
Methods:
Melanoma incidence rates were determined for 710 members of 311 melanoma families, defined as kindreds in which melanoma had occurred in two or more blood relatives. patients were classified either clinically or histologically as expressing dn. melanomas that occurred before the first examination were recorded, and patients were followed prospectively for new melanomas.
Results:
In prospective follow-up, the age-adjusted melanoma incidence rate was 1710/100,000 patient-years in family members with dn. in contrast, the rate was zero (no melanomas occurred) in family members without dn. for family members with dn, but without a history of melanoma, the age-adjusted incidence rate of melanoma was 413/100,000 patient-years, whereas the rate was 2779/100,000 patient-years in family members with dn and a history of melanoma.
Conclusions:
Dysplastic nevi and a history of melanoma are strong risk factors for subsequent melanoma. prognostic factors are greatly improved for patients with melanomas diagnosed in follow-up compared with the first two melanomas in each kindred. these findings warrant surveillance of individuals with dn who are members of familial melanoma kindreds.
π SIMILAR VOLUMES
## Abstract Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (highβ, intermediateβ, lowβdose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma
We studied a group of patients with or without individual or family history of melanoma for the occurrence of genetic alterations at microsatellite DNA sequences, usually referred to as microsatellite instability (MSI), and loss of heterozygosity (LOH). Microsatellite analysis of 3 markers located o
## Abstract Detection of circulating tumor cells (CTCs) might improve current staging procedures by identifying a subgroup of patients with minimal residual disease and thus a higher risk of disease recurrence. Forty patients with β₯2βmmβthick cutaneous melanoma with or without lymph node metastasis
## Abstract Recombinant plasmid DNA and attenuated poxviruses are under development as cancer and infectious disease vaccines. We present the results of a phase I clinical trial of recombinant plasmid DNA and modified vaccinia Ankara (MVA), both encoding 7 melanoma tumor antigen cytotoxic T lymphoc
The relationship between risk of cutaneous malignant melanoma and total body and site-specific naevus counts and other host factors was investigated in a Caucasian population aged 15-84 years in New South Wales, Australia. The study sample comprised 244 cases with melanoma diagnosed in 1989-1 993, a